Risk factors of synchronous peritoneal metastases in colorectal cancer: a meta-analysis

Yuanxin Zhang  
Sun Yat-sen University Sixth Affiliated Hospital  
https://orcid.org/0000-0002-9761-7933

Xiusen Qin  
Sun Yat-sen University Sixth Affiliated Hospital

Huaiming Wang  
Sun Yat-sen University Sixth Affiliated Hospital

Zhijie Wu  
Sun Yat-sen University Sixth Affiliated Hospital

Duo Liu  
Sun Yat-sen University Sixth Affiliated Hospital

Yang Du (✉ duyang9@mail.sysu.edu.cn)  
Sun Yat-sen University Sixth Affiliated Hospital

Hui Wang  
Sun Yat-sen University Sixth Affiliated Hospital

Research article

Keywords: Colorectal cancer, Synchronous peritoneal metastases, Risk factors, Meta-analysis

DOI: https://doi.org/10.21203/rs.3.rs-390534/v1

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

**Background:** Early detection of synchronous colorectal peritoneal metastasis (CPM) is difficult due to the absence of typical symptoms and the low accuracy of imaging examinations. Better knowledge of risk factors for synchronous CPM may be essential for early diagnosis and strengthening management. This study aimed to clarify the risk factors.

**Methods:** This meta-analysis was based on PRISMA guidelines. A systematic search of PubMed, Embase and Cochrane Library databases was performed. The pooled data was assessed by a random-effects model.

**Results:** 25 studies containing 171932 patients were included. Synchronous CPM was associated positively with female (OR 1.299; 1.118 to 1.509; P = 0.001), T4 (OR 12.331; 7.734 to 19.660; P < 0.001), N1-2 (OR 5.665; 3.628 to 8.848; P < 0.001), poorly differentiated grade (OR 2.560; 1.537 to 4.265; P < 0.001), right-sided colon cancer (OR 2.468; 2.050 to 2.970; P < 0.001), mucinous adenocarcinoma (OR 3.565; 2.095 to 6.064; P < 0.001), signet-ring cell carcinoma (OR 4.480; 1.836 to 10.933; P = 0.001), elevated serum CA19-9 (OR 12.868; 5.196 to 31.867; P < 0.001), PROK1/PROKR2-positive (OR 2.244; 1.031 to 4.884; P = 0.042) and BRAF mutations (OR 2.586; 1.674 to 3.994; P < 0.001). However, it's associated negatively with rectal cancer and non-mucinous adenocarcinoma, and not associated with KRAS, NRAS, PIK3CA mutations and MSI-H/dMMR.

**Conclusions:** These risk factors are the alerts that could predict the presence of synchronous CPM and contribute to strengthening management and optimal therapeutic strategy.

Background

Colorectal cancer (CRC) has become the third most common malignant tumors, with the second highest mortality worldwide[1]. Of all CRC, 8.3-15 percent have peritoneal metastases (PM)[2-4]. Up to 4.3-7.8 percent of CRC present with synchronous PM[2, 5-7]. PM is a well-known negative prognostic factor. Several recent large studies have shown substantially shorter survival with peritoneal metastasis of colorectal cancer (pmCRC) than metastases at other sites[8-10]. For example, the overall survival of pmCRC patients was 12.7 versus 17.6 months for metastases at other sites, with a significant p-value (p < 0.001)[9]. Therefore, this special type of metastatic disease of CRC deserves more attention.

Early detection of synchronous CPM is currently difficult due to the absence of typical symptoms and the low accuracy of non-invasive imaging examinations in nodules smaller than 5 mm[11-13]. In fact, a considerable proportion of synchronous CPM are unexpectedly detected during primary surgery[14]. Consequently, if that is the case, the extent of disease can only be evaluated during surgery, and treatment strategies are often selected at this time, which may determine a suboptimal treatment approach. Many hospitals are still lack of equipment for HIPEC nowadays. In addition, the concept and surgical proficiency of cytoreduction surgery may vary among different surgeons[5]. These may be unfavorable to the therapeutic strategies for CPM diagnosed during operation. Better knowledge of risk
factors for synchronous CPM would increase the level of suspicion in patients with no suggestive signs or symptoms, and thus allow physicians to treat these patients more adequately, such as more aggressive preoperative examination, proactive laparoscopic exploration or referring them to specialized centers.

Several studies have tried to determine the risk factors of synchronous CPM, but with heterogeneous outcomes, such as the location of primary tumor[8, 15], MSI-H[16-18]. Furthermore, many studies only focused on the aspect of clinicopathological characteristics of synchronous CPM, and thus they were lack of systematic and comprehensive analysis of molecular characteristics.

Further comprehensive understanding of its clinicopathological and molecular features may be necessary for early diagnosis and may help to enhance the management of patients at high risk of synchronous CPM. Therefore, a systematic review and meta-analysis of all studies comparing gender, tumor invasion depth, lymph node metastasis, differentiation, location of primary tumor, histology, serum CA19-9, PROK1/PROKR2, BRAF, KRAS, NRAS, PIK3CA and MSI-H/dMMR status between synchronous pmCRC and non-pmCRC was undertaken.

**Methods**

This systematic review and meta-analysis adhered to the recommendations of the Preferred Reporting Items of Systematic Reviews and Meta-analysis (PRISMA) statement[19]. PRISMA Checklist is available in supplementary Appendix 1.

**Study registration**

This study was registered at PROSPERO (Prospective Register of Systematic Reviews, www.crd.york.ac.uk/prospero). Number CRD42020198548.

**Eligibility criteria**

Colorectal peritoneal metastases can be divided into synchronous CPM and metachronous CPM. Synchronous CPM has different definitions[5, 6, 20]. Referring to the international consensus on colorectal liver metastases[21], synchronous CPM is defined as peritoneal metastases detected at or before diagnosis or surgery of the primary CRC; metachronous CPM is defined as those detected after curative surgery.

Comparative studies of primary colorectal tumor with or without synchronous PM involving data on clinicopathological and molecular characteristics were eligible for inclusion. The included studies need to use the recognized diagnostic criteria, as follows: the primary tumor's pathological diagnosis was confirmed; the tumor cells were primary in colorectal tumor; and the patient's synchronous PM was confirmed by imaging diagnosis before surgery, intraoperative exploration or histopathological examination.
The exclusion criteria were: (1) case reports, review articles and animal studies; (2) non-English publications; (3) studies that are not related to CRC or PM; (4) metachronous PM; (5) no analysis of the risk factors; (6) no comparator group; (7) no relevant data, including articles published only in abstract form as well as studies without complete data and inability to construct a 2×2 contingency table; (8) mixed primary tumor; (9) non-standardized histological type (10) synchronous CPM was not clearly or correctly defined.

Data sources and search strategy

We selected relevant studies by searching PubMed, Embase and the Cochrane CENTRAL Register of Controlled Trials. The following combined terms were used in the search: (peritoneal metastasis OR peritoneal metastases OR peritoneal carcinomatosis) AND (colorectal OR colon OR rectal). The latest search was implemented on 14 July 2020 and the earliest search was not limited in the relevant database.

Selection process

Two independent authors (Y.Z and X.Q) checked the title and abstract of each study, and studies that satisfied the potential eligibility were obtained for further full-text assessment. Disagreements were resolved by discussion with senior authors (Y.D or H.W) until consensus was achieved.

Data extraction

By using standardised forms, two independent authors (Y.Z and X.Q) extracted the data from each eligible study. The authors resolved disagreements by discussion with senior authors (Y.D or H.W). The following data were extracted from each eligible study: author, year of publication, country where the study was conducted, setting of centre, type of study, enrollment interval, number of primary CRC patients with or without synchronous PM, clinicopathological and molecular characteristics. In addition, the score of Newcastle–Ottawa Scale (N-O score) for eligible studies was also calculated and extracted.

Statistical analysis

We used Comprehensive Meta-Analysis (version 2.0) and Stata (version 12.0) for all statistical analyses. All pooled outcomes were determined using a random-effects model (DerSimonian-Laird method). In pooled analyses of associations between various clinicopathological-molecular factors and synchronous CPM, effect sizes were calculated as odds ratios (OR) with a 95 percent confidence interval (CI). The $\chi^2$-based Cochran Q test was used to assess heterogeneity between studies, in which $P < 0.1$ indicates the presence of heterogeneity[22]. We also did $I^2$ inconsistency testing to assess the extent of the heterogeneity between studies, with values greater than 50% regarded as moderate-to-high heterogeneity[23]. For significant heterogeneity, we tried to do sensitivity analysis or subgroup analysis to find its potential sources. Sensitivity analysis was performed by omitting each study sequentially to test the influence of each individual study on the pooled result. Publication bias was evaluated by visual
The quality of included studies was assessed using the Newcastle-Ottawa Scale[24], in which a score ≥ 6 indicates the high-quality of studies. The quality of studies was evaluated by examining 3 categories: patient selection, comparability of the 2 study groups, and assessment of exposure (maximum score 9), as was shown in the Newcastle-Ottawa Scale.

Results

Search and selection results

The initial search yielded a total of 9470 studies. After removal of duplicates, a total of 7659 studies were screened by analysis of title and abstract, and 7435 studies were removed because they met one or more exclusion criteria. The leaving 224 studies were then assessed for eligibility by full-text examination, and a further 199 were excluded for ineligibility. Reasons for exclusion were recorded. Finally, 25 studies[3, 8, 15-18, 25-43] were included in the final analysis (Fig. 1).

Study characteristics

Among the 25 included studies, 7 had a multicentre setting and 18 had a single centre design. Five of the included studies were prospectively performed; the remaining twenty were retrospective. 22 studies were considered of high quality (N-O score ≥ 6), and 3 studies were considered of low quality. Complete characteristics of the included studies are available in Table 1.

Factors not included in the quantitative synthesis

Six of clinicopathological and molecular factors could not be included in quantitative synthesis because they had only a single study of their subgroup, or their methodology did not permit pooling data. The six factors were serum CEA[25], serum CA125[32], CTGF (connective tissue growth factor)[40], DDR2 (discoidindomain receptor 2)[30], VIM (vimentin)[42], and TP53[28] respectively. We included these factors in table 1 for completeness, but not in the final quantitative synthesis through meta-analysis.

Finally, 21 studies about 13 factors were included in the quantitative synthesis through meta-analysis, 7 studies on gender, 4 studies on tumor invasion depth, 3 studies on lymph node metastasis, 5 studies on differentiation, 6 studies on primary tumor site, 7 studies on histology, 2 studies on serum CA19-9, 2 studies on PROK1/PROKR2, 9 studies on BRAF, 6 studies on KRAS, 2 studies on NRAS, 2 studies on PIK3CA and 4 studies on MSI-H/dMMR status.

Gender

Seven studies[8, 15, 17, 18, 25, 33, 41], including data on 160679 patients (30366 synchronous pmCRC, 130313 non-pmCRC) regarding gender, were included for eligibility in the meta-analysis. The pooled
analysis indicated that female was associated positively with synchronous CPM compared with male (OR 1.299; 95% CI, 1.118 to 1.509; P = 0.001) (Fig. 2a). There was significant heterogeneity (Cochran Q, P < 0.001; I² = 76.9 percent). In order to explore possible sources of heterogeneity, sensibility analysis was performed by omitting each study sequentially to test the influence of each individual study on the pooled result. When one study[17] was omitted, there was no significant heterogeneity (Cochran Q, P = 0.099; I² = 46.0 percent), with no noticeable influence on the pooled OR and confidence interval. It’s noteworthy that the rate of female in the synchronous CPM group was > 50 percent in that one study, but the others were < 50 percent.

**Tumor invasion depth**

Four studies[3, 15, 25, 41], including data on 19432 patients (809 synchronous pmCRC, 18623 non-pmCRC) regarding tumor invasion depth, were included for eligibility in the meta-analysis. The pooled analysis indicated that T4 was associated positively with synchronous CPM compared with T1-3 (OR 12.331; 95% CI, 7.734 to 19.660; P < 0.001) (Fig. 2b). There was significant heterogeneity (Cochran Q, P = 0.009; I² = 74.2 percent). When one study[41] was omitted through sensibility analysis, there was no significant heterogeneity (Cochran Q, P = 0.593; I² = 0 percent), with no noticeable influence on the pooled result.

**Lymph node metastasis**

Three studies[3, 15, 41], including data on 16097 patients (702 synchronous pmCRC, 15395 non-pmCRC) comparing lymph node metastasis, were included for eligibility in the meta-analysis. The pooled analysis indicated that N1-2 was associated positively with synchronous PM compared with N0 (OR 5.665; 95% CI, 3.628 to 8.848; P < 0.001) (Fig. 2c). There was significant heterogeneity (Cochran Q, P = 0.068; I² = 62.7 percent). When one study[3] was omitted through sensibility analysis, there was no significant heterogeneity (Cochran Q, P = 0.765; I² = 0 percent), with no noticeable influence on the pooled result.

**Differentiation**

Five studies[15, 17, 25, 41, 43], including data on 108360 patients (21986 synchronous pmCRC, 86374 non-pmCRC) comparing differentiation, were included for eligibility in the meta-analysis. The pooled analysis indicated that poorly differentiated grade was associated positively with synchronous CPM compared with well/moderately differentiated grade (OR 2.560; 95% CI, 1.537 to 4.265; P < 0.001) (Fig. 2d). There was significant heterogeneity (Cochran Q, P < 0.001; I² = 94.5 percent). When one study[17] was omitted through sensibility analysis, there was no significant heterogeneity (Cochran Q, P = 0.636; I² = 0 percent), with no noticeable influence on the pooled result.

**Location of primary tumor**

Six studies[3, 8, 15, 18, 25, 41] including data on 24331 patients (1610 synchronous pmCRC, 22721 non-pmCRC) regarding right-sided colon cancer were included for eligibility in the meta-analysis. Synchronous
CPM was associated positively with right-sided colon cancer location (OR 2.468; 95% CI, 2.050 to 2.970; P < 0.001) (Fig. 3a). There was no significant heterogeneity (Cochran Q, P = 0.119; I² = 42.9 percent).

Six studies[3, 8, 15, 18, 25, 41] including data on 24331 patients (1610 synchronous pmCRC, 22721 non-pmCRC) regarding left-sided colon cancer were included for eligibility in the meta-analysis. Synchronous CPM was not associated with left-sided colon cancer location (OR 1.000; 95% CI, 0.761 to 1.314; P = 0.998) (Fig. 3b). There was significant heterogeneity (Cochran Q, P = 0.004; I² = 71.4 percent). When one study[15] was omitted through sensibility analysis, there was less significant heterogeneity (Cochran Q, P = 0.049; I² = 58.0 percent), with no noticeable influence on the pooled result.

Five studies[3, 8, 18, 25, 41] including data on 23278 patients (1519 synchronous pmCRC, 21759 non-pmCRC) regarding rectal cancer were included for eligibility in the meta-analysis. Synchronous CPM was associated negatively with rectal cancer location (OR 0.323; 95% CI, 0.284 to 0.368; P < 0.001) (Fig. 3c). There was no significant heterogeneity (Cochran Q, P = 0.969; I² = 0 percent).

**Histology**

Six studies[3, 26, 36, 38, 41, 43] including data on 24252 patients (1600 synchronous pmCRC, 22652 non-pmCRC) regarding non-mucinous adenocarcinoma (NMC) were included for eligibility in the meta-analysis. Synchronous CPM was associated negatively with NMC (OR 0.319; 95% CI, 0.237 to 0.429; P < 0.001) (Fig. 4a). There was significant heterogeneity (Cochran Q, P = 0.005; I² = 70.4 percent). When one study[36] was omitted through sensibility analysis, there was no significant heterogeneity (Cochran Q, P = 0.106; I² = 47.5 percent), with no noticeable influence on the pooled OR and confidence interval.

Seven studies[3, 17, 26, 36, 38, 41, 43] including data on 154377 patients (29448 synchronous pmCRC, 124929 non-pmCRC) regarding mucinous adenocarcinoma (MC) were included for eligibility in the meta-analysis. Synchronous CPM was associated positively with MC (OR 3.565; 95% CI, 2.095 to 6.064; P < 0.001) (Fig. 4b). There was significant heterogeneity (Cochran Q, P < 0.001; I² = 97.1 percent). In order to explore possible sources of heterogeneity, subgroup analysis was performed. Two studies[17, 36] were divided into the subgroup one that had no significant heterogeneity (Cochran Q, P = 0.228; I² = 31.2 percent), with no noticeable influence on the pooled result, and the others[3, 26, 38, 41, 43] were divided into the subgroup two that also had no significant heterogeneity (Cochran Q, P = 0.174; I² = 37.0 percent), with no noticeable influence on the pooled result. The subgroup one had much higher OR value in each study than subgroup two.

Three studies[3, 26, 38] including data on 5741 patients (673 synchronous pmCRC, 5068 non-pmCRC) regarding signet-ring cell carcinoma (SRCC) were included for eligibility in the meta-analysis. Synchronous CPM was associated positively with SRCC (OR 4.480; 95% CI, 1.836 to 10.933; P = 0.001) (Fig. 4c). There was significant heterogeneity (Cochran Q, P = 0.036; I² = 69.7 percent). When one study[3] was omitted through sensibility analysis, there was no significant heterogeneity (Cochran Q, P = 0.656; I² = 0 percent), with no noticeable influence on the pooled result. It's noteworthy that the study had a much higher OR value.
Serum CA19-9

Two studies[25, 39], including data on 728 patients (24 synchronous pmCRC, 704 non-pmCRC) regarding serum CA19-9 status, were included for eligibility in the meta-analysis. Serum CA19-9 level of up to 37.0 u/ml was taken as upper cut-off values for reference ranges. Synchronous CPM was associated positively with elevated serum CA19-9 (OR 12.868; 95% CI, 5.196 to 31.867; P < 0.001) (Fig. 5a). There was no significant heterogeneity (Cochran Q, P = 0.710; I² = 0 percent).

PROK1/PROKR2

Two studies[34, 37], including data on 944 patients (29 synchronous pmCRC, 915 non- pmCRC) regarding PROK1/PROKR2 status, were included for eligibility in the meta-analysis. Synchronous CPM was associated positively with PROK1/PROKR2-positive (OR 2.244; 95% CI, 1.031 to 4.884; P = 0.042) (Fig. 5b). There was no significant heterogeneity (Cochran Q, P = 0.344; I² = 0 percent).

BRAF status

Nine studies[8, 16, 18, 27-29, 31, 33, 35], including data on 4979 patients (704 synchronous pmCRC, 4275 non-pmCRC) regarding BRAF status, were included for eligibility in the meta-analysis. Synchronous PM was associated positively with BRAF mutations (OR 2.586; 95% CI, 1.674 to 3.994; P < 0.001) (Fig. 5c). There was significant heterogeneity (Cochran Q, P = 0.019; I² = 56.3 percent). When one study[28] was omitted through sensibility analysis, there was no significant heterogeneity (Cochran Q, P = 0.073; I² = 45.9 percent), with no noticeable influence on the pooled OR and confidence interval. It’s clearly seen that the study has a smaller sample size.

KRAS status

Six studies[8, 16-18, 28, 33], including data on 134197 patients (28362 synchronous pmCRC, 105835 non-pmCRC) regarding KRAS status, were included for eligibility in the meta-analysis. Synchronous CPM was not associated with KRAS mutations (OR 0.972; 95% CI, 0.576 to 1.638; P = 0.914) (Fig. 6a). There was significant heterogeneity (Cochran Q, P < 0.001; I² = 92.4 percent). When one study[17] was omitted through sensibility analysis, there was no significant heterogeneity (Cochran Q, P = 0.774; I² = 0 percent), with no noticeable influence on the pooled result. It’s noteworthy that the rate of KRAS mutations in the synchronous PM group was much lower in the study.

NRAS status

Two studies[16, 28], including data on 731 patients (43 synchronous pmCRC, 688 non- pmCRC) regarding NRAS status, were included for eligibility in the meta-analysis. Synchronous CPM was not associated with NRAS mutations (OR 1.140; 95% CI, 0.133 to 9.748; P = 0.905) (Fig. 6b). There was no significant heterogeneity (Cochran Q, P = 0.373; I² = 0 percent).

PIK3CA status
Two studies[16, 33], including data on 897 patients (93 synchronous pmCRC, 804 non-pmCRC) regarding PIK3CA status, were included for eligibility in the meta-analysis. Synchronous CPM was not associated with PIK3CA mutations (OR 0.667; 95% CI, 0.289 to 1.540; P = 0.343) (Fig. 6c). There was no significant heterogeneity (Cochran Q, P = 0.343; I² = 0 percent).

**MSI-H/dMMR status**

Four studies[16-18, 31], including data on 131015 patients (27922 synchronous pmCRC, 103093 non-pmCRC) regarding MSI-H/dMMR status, were included for eligibility in the meta-analysis. Synchronous CPM was not associated with MSI-H/dMMR (OR 1.087; 95% CI, 0.351 to 3.367; P = 0.885) (Fig. 6d). There was significant heterogeneity (Cochran Q, P = 0.097; I² = 52.5 percent). When one study[18] was omitted through sensibility analysis, there was no significant heterogeneity (Cochran Q, P = 0.153; I² = 46.6 percent), with no noticeable influence on the pooled result.

**Publication bias**

No significant publication bias was found, according to visual inspection of funnel plot and to Begg’s test (supplementary Fig. S1-S5).

**Discussion**

We found that synchronous CPM was associated positively with female, PROK1/PROKR2-positive, right-sided colon cancer location, poorly differentiated grade, BRAF mutations, mucinous adenocarcinoma, signet-ring cell carcinoma, N1-2, T4 and elevated serum CA19-9 (ascendingly sequenced by the value of odds ratios). Our study has provided an extensive analysis of the association between synchronous CPM and clinicopathological-molecular features, especially the molecular characteristics compared with the previously published studies[44-47]. In addition, several studies have different conclusions about the association between MSI-H and synchronous CPM, although MSI-H is a poor prognostic factor in metastatic colorectal cancer[48, 49]. Nonetheless, we found that MSI-H was irrelevant with synchronous CPM in this study. The meta-analytical techniques could increase the volume, which may cause more sufficient statistical power.

Based on the hypothesis that phenotype and the subsequent clinical behavior of CPM is driven by underlying biological mechanisms, readouts of disease biology will contribute to more precise identification of suitable patients and guidance of therapy. This is one of the critical future research targets in CPM. The potential mechanisms of risk factors that associated positively with synchronous CPM are discussed as follows. Due to a longer asymptomatic period, right-sided colon tumors are usually larger in diameter when diagnosed than left-sided colon tumors. Larger neoplasms infiltrate the surface of serosa over a larger area, so it may lead to increased abscission of cancer cells into the peritoneal cavity. In addition, typical genetic differences between right-sided and left-sided colon tumors have been found, such as BRAF status, and these genotypes may bring about a fenotype with a different probability to be associated with synchronous CPM[50]. Several studies have shown that mucinous histologic type
has a poor prognostic impact, including a higher tendency to peritoneal carcinomatosis and a lower efficacy of oxaliplatin and irinotecan-based chemotherapy[51-53]. A more advanced T stage is associated positively with the presentation of peritoneal carcinomatosis, with the potential mechanism that peritoneal carcinomatosis is caused by serosal infiltration of the malignant tumor and subsequent abscission of cancer cells into the peritoneal cavity[54]. Regarding peritoneal tumor spread, CA19-9 was shown to interact with E- and P-selectins expressed on human mesothelial and endothelial cells in the peritoneum[25, 55]. Prokineticin1 (PROK1) is a known ligand of Prokineticin-receptor2 (PROKR2) and transduces important molecular signals to induce physiological changes. The PROK1 protein was identified as a vascular endothelial growth factor. Increased PROK1 expression is associated with angiogenesis involving hematogenous metastasis[34, 37]. Besides direct invasion and hematogenous spread, peritoneal carcinomatosis could be occurred by lymphatic dissemination, which supports the risk factor of N1-2[54, 56, 57].

Some studies once defined the degree of risk of developing colorectal peritoneal carcinomatosis[58, 59]. A high risk of synchronous CPM should modify the management strategy of this special type of metastatic disease, with the following suggestions[5, 58]. First, in CRC patients at high risk of developing synchronous PM, a more aggressive preoperative examination, such as PET-CT, MRI diffusion-weighted and so on, is suggested to be performed to confirm whether there is synchronous PM. Then, if PM is suspected on preoperative imaging, we could propose laparoscopic exploration of the abdominal cavity to assess the extent of the disease and to obtain histological confirmation. Eventually, if the synchronous PM is diagnosed, surgeons are expected to describe the extent of the disease and to determine whether aggressive treatment including complete CRS plus HIPEC should be carried out in patients.

There are some limitations in this study. Firstly, the non-English studies were excluded, with the language bias. Secondly, the risk associated with T4a vs. T4b stage was not analyzed because the specific data was absent in the included studies. Thirdly, factors such as T4 stage and N1-2 stage are of little help, because they can be poorly assessed preoperatively. Finally, the number of included studies about CA19-9, PROK1/PROKR2, NRAS, PIK3CA status is small, which may cause limited statistical power.

**Conclusions**

To our knowledge, this is the first meta-analysis to reveal the clinicopathological and molecular features of synchronous pmCRC compared to non-pmCRC. These evidence-based predictive factors of synchronous CPM are conducive to enhance the management and select optimal therapeutic strategy.

**Abbreviations**

PRISMA: Preferred Reporting Items of Systematic Reviews and Meta-analysis; PROSPERO: Prospective Register of Systematic Reviews; N-O score: Score of Newcastle–Ottawa Scale; OR: odds ratios; CI: Confidence interval; CPM: Colorectal peritoneal metastasis; CRC: Colorectal cancer; PM: Peritoneal metastases; pmCRC: Peritoneal metastasis of colorectal cancer; CTGF: Connective tissue growth factor;
Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

This study was sponsored by the Guangzhou Science and Technology Plan Project (No. 201704020059). The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Authors’ contributions

H.W designed the study. D.L performed statistical analysis. Y.Z and X.Q wrote, reviewed, and edited the manuscript. Y.D and Z.W performed data interpretation. Y.Z, X.Q, Y.D and H.W performed study selection and data extraction. All authors read and approved the final draft.

Acknowledgements

Not applicable

References

1. World Health Organization: International Agency for Research on Cancer. GLOBOCAN 2020: Estimated cancer incidence, mortality and prevalence worldwide in 2020. https://gco.iarc.fr/today.
2. Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A: Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg 2012, 99:699-705.
3. Kerscher AG, Chua TC, Gasser M, Maeder U, Kunzmann V, Isbert C, Germer CT, Pelz JOW: Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades. *Br J Cancer* 2013, 108:1432-1439.

4. Hallam S, Tyler R, Price M, Beggs A, Youssef H: Meta-analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy. *BJS Open* 2019, 3:585-594.

5. Mo S, Dai W, Xiang W, Li Q, Wang R, Cai G: Predictive factors of synchronous colorectal peritoneal metastases: Development of a nomogram and study of its utilities using decision curve analysis. *Int J Surg* 2018, 54:149-155.

6. Jayne DG, Fook S, Seow-Choen CLAF: Peritoneal carcinomatosis from colorectal cancer. *Br J Surg* 2002, 89:1545-1550.

7. Quere P, Facy O, Manfredi S, Jooste V, Faivre J, Lepage C, Bouvier AM: Epidemiology, Management, and Survival of Peritoneal Carcinomatosis from Colorectal Cancer: A Population-Based Study. *Dis Colon Rectum* 2015, 58:743-752.

8. Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, Saltz L, Punt C, Koopman M, Tournigand C *et al.* Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. *Lancet Oncol* 2016, 17:1709-1719.

9. Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ: Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. *J Clin Oncol* 2012, 30:263-267.

10. Klaver YL, Simkens LH, Lemmens VE, Koopman M, Teerenstra S, Bleichrodt RP, de Hingh IH, Punt CJ: Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. *Eur J Surg Oncol* 2012, 38:617-623.

11. Elias D, Honoré C, Dumont F, Ducreux M, Boige V, Malka D, Burtin P, Dromain C, Goéré D: Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. *Ann Surg* 2011, 254:289-293.

12. Verwaal VJ, Zoetmulder FA: Follow-up of patients treated by cytoreduction and chemotherapy for peritoneal carcinomatosis of colorectal origin. *Eur J Surg Oncol* 2004, 30:280-285.

13. Koh JL, Yan TD, Glenn D, Morris DL: Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. *Ann Surg Oncol* 2009, 16:327-333.

14. Sato H, Toyama K, Koide Y, Ozeki S, Hatta K, Maeda K: Prognoses and treatment strategies for synchronous peritoneal dissemination of colorectal carcinoma. *Surg Today* 2016, 46(7):860-871.

15. Sjo OH, Berg M, Merok MA, Kolberg M, Svindland A, Lothe RA, Nesbakken A: Peritoneal carcinomatosis of colon cancer origin: Highest incidence in women and in patients with right-sided
tumors. *J SURG ONCOL* 2011, 104:792-797.

16. Smith CG, Fisher D, Claes B, Maughan TS, Idziaszczyk S, Peuteman G, Harris R, James MD, Meade A, Jasani B *et al*.: Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab. *CLIN CANCER RES* 2013, 19:4104-4113.

17. Sherman SK, Schuitevoerder D, Chan CHF, Turaga KK: Metastatic Colorectal Cancers with Mismatch Repair Deficiency Result in Worse Survival Regardless of Peritoneal Metastases. *ANN SURG ONCOL* 2020, 27:5074-5083.

18. Shelygin YA, Pospekhova NI, Shubin VP, Kashnikov VN, Frolov SA, Sushkov OL, Achkasov SI, Tsukanov AS: Epithelial-Mesenchymal Transition and Somatic Alteration in Colorectal Cancer with and without Peritoneal Carcinomatosis. *BIOMED RES INT* 2014, 2014:629496.

19. Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *ANN INTERN MED* 2009, 151:264-269.

20. Veld JV, Wisselink DD, Amelung FJ, Consten E, de Wilt J, de Hingh I, Bemelman WA, van Hooft JE, Tanis PJ: Synchronous and Metachronous Peritoneal Metastases in Patients with Left-Sided Obstructive Colon Cancer. *ANN SURG ONCOL* 2020, 27:2762-2773.

21. René Adam ADGJ, Kunstlinger ELGP, Alberto Sobrero CTST, Vauthey LP: Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. *CANCER TREAT REV* 2015, 41:729-741.

22. Higgins JPT, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. *BMJ* 2003, 327:557-560.

23. Higgins JPT, Thompson SG: Quantifying heterogeneity in a meta-analysis. *STAT MED* 2002, 21:1539-1558.

24. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M *et al*.: The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta Analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm

25. Kaneko M, Ishihara S, Murono K, Sasaki K, Otani K, Yasuda K, Nishikawa T, Tanaka T, Kiyomatsu T, Hata K *et al*.: Carbohydrate Antigen 19-9 Predicts Synchronous Peritoneal Carcinomatosis in Patients with Colorectal Cancer. *ANTICANCER RES* 2017, 37:865-870.

26. SONG WWSH: Clinicopathologic features and survival of patients with colorectal mucinous, signet-ring cell or non-mucinous adenocarcinoma: experience at an institution in southern China. *CHINESE MED J-PEKING* 2009, 122:1486-1491.

27. Eurboonyanun K, Lahoud RM, Kordbacheh H, Pourvaziri A, Promsorn J, Chadbunchachai P, O Shea A, Atre ID, Harisinghani M: Imaging predictors of BRAF mutation in colorectal cancer. *Abdom Radiol (NY)* 2020, 45:2336-2344.

28. Sayagués JM, Del Carmen S, Abad MDM, Corchete LA, Bengoechea O, Anduaga MF, Baldeón MJ, Cruz JJ, Alcazar JA, Angoso M *et al*.: Combined assessment of the TNM stage and BRAF mutational status at diagnosis in sporadic colorectal cancer patients. *Oncotarget* 2018, 9:24081-24096.
29. Cheng H, Lin J, Chen W, Jiang J, Yang S, Chang S: Clinical significance of the BRAFV600E mutation in Asian patients with colorectal cancer. *INT J COLORECTAL DIS* 2018, 33:1173-1181.

30. Sasaki S, Ueda M, Iguchi T, Kaneko M, Nakayama H, Watanabe T, Sakamoto A, Mimori K: DDR2 Expression Is Associated with a High Frequency of Peritoneal Dissemination and Poor Prognosis in Colorectal Cancer. *ANTICANCER RES* 2017, 37:2587-2591.

31. Jang MH, Kim S, Hwang DY, Kim WY, Lim SD, Kim WS, Hwang TS, Han HS: BRAF-Mutated Colorectal Cancer Exhibits Distinct Clinicopathological Features from Wild-Type BRAF-Expressing Cancer Independent of the Microsatellite Instability Status. *J KOREAN MED SCI* 2017, 32:38-46.

32. Huang C, Jiang J, Chang S, Lin J, Yang S: Serum CA125 concentration as a predictor of peritoneal dissemination of colorectal cancer in men and women. *Medicine (Baltimore)* 2016, 95:e5177.

33. Sasaki Y, Hamaguchi T, Yamada Y, Takahashi N, Shoji H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K et al.: Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis. *Asian Pac J Cancer Prev* 2016, 17:539-543.

34. Goi T, Kurebayashi H, Ueda Y, Naruse T, Nakazawa T, Koneri K, Hirono Y, Katayama K, Yamaguchi A: Expression of prokineticin-receptor2(PK-R2) is a new prognostic factor in human colorectal cancer. *Oncotarget* 2015, 6:31758-31766.

35. Cremolini C, Di Bartolomeo M, Amatu A, Antoniotti C, Moretto R, Berenato R, Perrone F, Tamborini E, Aprile G, Lonardi S et al.: BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. *ANN ONCOL* 2015, 26:2092-2097.

36. Jimi S, Hotokezaka M, Ikeda T, Uchiyama S, Hidaka H, Maehara N, Ishizaki H, Chijiwa K: Clinicopathological features, postoperative survival and prognostic variables for cancer-related survival in patients with mucinous colorectal carcinoma. *SURG TODAY* 2014, 45:329-334.

37. Nakazawa T, Goi T, Hirono Y, Yamaguchi A: Prokineticin 1 Protein Expression is a Useful New Prognostic Factor for Human Sporadic Colorectal Cancer. *ANN SURG ONCOL* 2014, 22:1496-1503.

38. Hugen N, van de Velde CJH, de Wilt JHW, Nagtegaal ID: The clinical utility of the local inflammatory response in colorectal cancer. *EUR J CANCER* 2013, 50:309-319.

39. Yu H, Son GM, Joh YG: The clinical significance of preoperative serum levels of carbohydrate antigen 19-9 in colorectal cancer. *J Korean Surg Soc* 2013, 84:231-237.

40. Lin BR, Chang CC, Chen RJC, Jeng YM, Liang JT, Lee PH, Chang KJ, Kuo ML: Connective Tissue Growth Factor Acts as a Therapeutic Agent and Predictor for Peritoneal Carcinomatosis of Colorectal Cancer. *CLIN CANCER RES* 2011, 17:3077-3088.

41. Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JWW, de Hingh IH: Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: A population-based study. *INT J CANCER* 2011, 128:2717-2725.

42. Shirahata A, Sakuraba K, Goto T, Saito M, Ishibashi K, Kigawa G, Nemoto H, Hibi K: Detection of vimentin (VIM) methylation in the serum of colorectal cancer patients. *ANTICANCER RES* 2010, 30:5015-5018.
43. Akino F, Mitomi H, Nakamura T, Ohtani Y, Ichinoe M, Okayasu I: High apoptotic activity and low epithelial cell proliferation with underexpression of p21(WAF1/CIP1) and p27Kip1 of mucinous carcinomas of the colorectum: comparison with well-differentiated type. AM J CLIN PATHOL 2002, 117:908-915.

44. Lurvink RJ, Bakkers C, Rijken A, van Erning FN, Nienhuijs SW, Burger JW, Creemers GJ, Verhoef C, Lemmens VE, De Hingh IH: Increase in the incidence of synchronous and metachronous peritoneal metastases in patients with colorectal cancer: A nationwide study. European Journal of Surgical Oncology 2020, S0748-7983:31031-31033.

45. Li M, Sun K, Dai W, Xiang W, Zhang Z, Zhang R, Wang R, Li Q, Mo S, Han L et al: Preoperative prediction of peritoneal metastasis in colorectal cancer using a clinical-radiomics model. EUR J RADIOL 2020, 132:109326.

46. Goéré D: Incidence and prognosis of synchronous colorectal carcinomatosis: evolution since 1985? FUTURE ONCOL 2011, 7:1265-1268.

47. Mo S, Dai W, Xiang W, Li Q, Wang R, Cai G: Predictive factors of synchronous colorectal peritoneal metastases: Development of a nomogram and study of its utilities using decision curve analysis. INT J SURG 2018, 54:149-155.

48. Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, Fisher D, Kaplan R, Quirke P, Seymour MT, Richman SD et al: Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. CLIN CANCER RES 2014, 20:5322-5330.

49. Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J: Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. CANCER-AM CANCER SOC 2011, 117(20):4623-4632.

50. Glebov OK, Rodriguez LM, Nakahara K, Jenkins J, Cliatt J, Humbyrd CJ, DeNobile J, Soballe P, Simon R, Wright G et al: Distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol Biomarkers Prev 2003, 12:755-762.

51. Catalano V, Loupakis F, Graziano F, Torresi U, Bisonni R, Mari D, Fornaro L, Baldelli AM, Giordani P, Rossi D et al: Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy. Br J Cancer 2009, 100:881-887.

52. Yan TD, Chu F, Links M, Karn PC, Glenn D, Morris DL: Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma: non-mucinous tumour associated with an improved survival. Eur J Surg Oncol 2006, 32:1119-1124.

53. Nozoe T, Anai H, Nasu S, Sugimachi K: Clinicopathological characteristics of mucinous carcinoma of the colon and rectum. J SURG ONCOL 2000, 75:103-107.

54. Ceelen WPD, Bracke MEP: Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment. LANCET ONCOL 2009, 10:72-79.
55. Gebauer F, Wicklein D, Stübke K, Nehmann N, Schmidt A, Salamon J, Peldschus K, Nentwich MF, Adam G, Tolstonog G et al: Selectin binding is essential for peritoneal carcinomatosis in a xenograft model of human pancreatic adenocarcinoma in pfp--/rag2-- mice. GUT 2013, 62:741-750.

56. Hansen E, Wolff N, Knuechel R, Ruschoff J, Hofstaedter F, Taeger K: Tumor cells in blood shed from the surgical field. Arch Surg 1995, 130:387-393.

57. Pretzsch E, Bösch F, Neumann J, Ganschow P, Bazhin A, Guba M, Werner J, Angele M: Mechanisms of Metastasis in Colorectal Cancer and Metastatic Organotropism: Hematogenous versus Peritoneal Spread. J ONCOL 2019, 2019:7407190.

58. Goéré D: Incidence and prognosis of synchronous colorectal carcinomatosis: evolution since 1985? FUTURE ONCOL 2011, 7:1265-1268.

59. Honoré C, Goéré D, Souadka A, Dumont F, Elias D: Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review. ANN SURG ONCOL 2013, 20:183-192.

Table
Table 1 Characteristics of included studies

| Author          | Year | Country | Multicentre/unicentre | Study type | Enrollment interval | Number of patient with synchronous PM | Number of patients without synchronous PM | Clinical, pathological and biological characteristics |
|-----------------|------|---------|-----------------------|------------|--------------------|----------------------------------------|---------------------------------------------|-----------------------------------------------------|
| Sherman et al17 | 2020 | USA     | M                     | Retro      | 2016-2016          | 1527                                   | 102277                                      | Gender, Differentiation, Histology, KRAS, MSH6/MMR |
| Eroboosumun et al27 | 2020 | USA     | U                     | Retro      | 2004-2018          | 17                                     | 133                                         | BRAF                                              |
| Cheng et al20   | 2018 | Taiwan  | U                     | Retro      | 2006-2013          | 76                                     | 260                                         | BRAF                                              |
| Sayagouicki et al28 | 2018 | Spain   | U                     | Retro      | -                  | 7                                      | 80                                          | BRAF, KRAS, NRAS, TP53                            |
| Konoko et al29  | 2017 | Japan   | U                     | Retro      | 2009-2015          | 12                                     | 383                                         | Gender, Tumor location, T stage, Differentiation, CA19-9, CEA |
| Jang et al31    | 2017 | Korea   | U                     | Retro      | 2011-2014          | 30                                     | 319                                         | BRAF, MSH6/MMR                                   |
| Sasaki et al32  | 2017 | Japan   | U                     | Retro      | 2009-2014          | 13                                     | 50                                          | DDR2                                             |
| Franko et al34  | 2016 | AKCD    | M                     | Pro        | 1997-2008          | 1371                                   | 9160                                        | Gender, Tumor location, BRAF, KRAS                |
| Sasaki et al35  | 2016 | Japan   | U                     | Retro      | 2006-2011          | 117                                     | 409                                         | Gender, BRAF, KRAS, PIK3CA                        |
| Huang et al36   | 2016 | Taiwan  | U                     | Retro      | 2006-2010          | 14                                     | 500                                         | CA125                                             |
| Goi et al37     | 2015 | Japan   | U                     | Retro      | 1996-2007          | 9                                      | 315                                         | PROK1/PROKR2                                     |
| Cremerini et al38 | 2015 | Italy   | M                     | Retro      | 2006-2014          | 138                                    | 481                                         | BRAF                                              |
| Shelygin et al39 | 2014 | Russia  | U                     | Retro      | 2012-2014          | 20                                     | 38                                          | Gender, Tumor location, BRAF, MSH6/MMR            |
| Jini et al40    | 2014 | Japan   | U                     | Retro      | 1991-2006          | 29                                     | 397                                         | Histology                                        |
| Nakazawa et al41 | 2014 | Japan   | U                     | Retro      | 1996-2007          | 20                                     | 600                                         | PROK1/PROKR2                                     |
| Kerscher et al42 | 2013 | Germany | U                     | Pro        | 1986-2009          | 115                                     | 2150                                        | Tumor location, T stage, LN+, Histology           |
| Smith et al43   | 2013 | UK      | M                     | Pro        | 2003-2005          | 36                                     | 611                                         | BRAF, KRAS, MSH6/MMR, NRAS, PIK3CA                |
| Hugen et al44   | 2013 | Netherlands | M                | Retro      | 1991-2010          | 425                                    | 1253                                        | Histology                                        |
| Yu et al45      | 2013 | Korea   | U                     | Pro        | 2008-2011          | 12                                     | 121                                         | CA19-9                                           |
| Sjo et al46     | 2011 | Norway  | M                     | Pro        | 1993-2006          | 94                                     | 1030                                        | Gender, Tumor location, T stage, LN+, Histology   |
| Lemmens et al47 | 2011 | Netherlands | M                | Retro      | 1995-2008          | 904                                     | 17007                                       | Gender, Tumor location, T stage, LN+, Differentiation, Histology |
| Liu et al48     | 2011 | Taiwan  | U                     | Retro      | 2001-2003          | 37                                     | 99                                          | CTGF                                             |
| Shirahata et al49 | 2010 | Japan   | U                     | Retro      | -                  | 5                                      | 39                                          | VIM                                              |
| Song et al50    | 2009 | China   | U                     | Retro      | 1994-2007          | 149                                    | 1857                                        | Histology                                        |
| Akino et al51   | 2002 | Japan   | U                     | Retro      | 1986-1999          | 46                                     | 610                                         | Histology, Differentiation                        |

M, multicentre; U, unicentre; Retro, retrospective; Pro, prospective; DDR2, discoidin-domain receptor 2; PROK1, prokineticin 1; PROKR2, prokineticin receptor 2; CTGF, connective tissue growth factor; VIM, vimentin; LN+, lymph node metastasis.

Figures
Figure 1

Flow diagram showing search and selection of studies
Figure 2

Forest plot for female, T4, N1-2 and poorly differentiated grade. Odds ratios are shown with 95% CI. A, non-pmCRC; B, synchronous pmCRC. a, female (n = 160679; p < 0.001; Cochran Q 25.9, 6 df, p < 0.001; I², 76.9). b, T4 (n = 19432; p < 0.001; Cochran Q 11.6, 3 df, p = 0.009; I², 74.2). c, N1-2 (n = 16097; p < 0.001; Cochran Q 5.3, 2 df, p = 0.068; I², 62.7). d, poorly differentiated grade (n = 108360; p < 0.001; Cochran Q 73.0, 4 df, p < 0.001; I², 94.5).
Figure 3

Forest plot for right-sided colon, left-sided colon and rectum. Odds ratios are shown with 95% CI. A, non-pmCRC; B, synchronous pmCRC. a, right-sided colon (n = 24331; p < 0.001; Cochran Q 8.7, 5 df, p = 0.119; I², 42.9). b, left-sided colon (n = 24331; p = 0.998; Cochran Q 17.5, 5 df, p = 0.004; I², 71.4). c, rectum (n = 23278; p < 0.001; Cochran Q 0.5, 4 df, p = 0.969; I², 0).
Figure 4

Forest plot for non-mucinous adenocarcinoma (NMC), mucinous adenocarcinoma (MC) and signet-ring cell carcinoma (SRCC). Odds ratios are shown with 95% CI. A, non-pmCRC; B, synchronous pmCRC. a, NMC (n = 24252; p < 0.001; Cochran Q 16.9, 5 df, p = 0.005; I², 70.4). b, MC (n = 154377; p = 0.998; Cochran Q 207.0, 6 df, p < 0.001; I², 97.1). c, SRCC (n = 5741; p = 0.001; Cochran Q 6.6, 2 df, p = 0.036; I², 69.7).
Figure 5

Forest plot for serum CA19-9, PROK1/PROKR2 and BRAF. Odds ratios are shown with 95% CI. A, non-pmCRC; B, synchronous pmCRC. a, serum CA19-9 (n = 728; p < 0.001; Cochran Q 0.1, 1 df, p = 0.710; I², 0). b, PROK1/PROKR2 (n = 944; p = 0.042; Cochran Q 0.8, 1 df, p = 0.344; I², 0). c, BRAF (n = 4979; p < 0.001; Cochran Q 18.3, 8 df, p = 0.019; I², 56.3).
Figure 6

Forest plot for KRAS, NRAS, PIK3CA and MSI-H/dMMR. Odds ratios are shown with 95% CI. A, non-pmCRC; B, synchronous pmCRC. a, KRAS (n = 134197; p = 0.914; Cochran Q 65.8, 5 df, p < 0.001; I², 92.4). b, NRAS (n = 731; p = 0.905; Cochran Q 0.7, 1 df, p = 0.373; I², 0). c, PIK3CA (n = 897; p = 0.343; Cochran Q 0.6, 1 df, p = 0.415; I², 0). d, MSI-H/dMMR (n = 131015; p = 0.885; Cochran Q 6.3, 3 df, p = 0.097; I², 52.5).
Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryFig.S1S5.docx
- SupplementaryAppendix1.doc